Skip to Content

Tikosyn

Active Substance: dofetilide
Common Name: dofetilide
ATC Code: C01BD04
Marketing Authorisation Holder: Pfizer Limited
Active Substance: dofetilide
Status: Withdrawn
Authorisation Date: 1999-11-29
Therapeutic Area: Atrial Flutter Atrial Fibrillation
Pharmacotherapeutic Group: Cardiac therapy

Therapeutic Indication

Tikosyn is a Class III antiarrhythmic agent that is indicated for the following:

  • Conversion of persistent atrial fibrillation or atrial flutter to normal sinus rhythm in patients in whom cardioversion by electrical means is not appropriate and in whom the duration of the arrhythmic episode is less than 6 months (see section 5.1).
  • Maintenance of sinus rhythm (after conversion) in patients with persistent atrial fibrillation or atrial flutter. Because TIKOSYN can cause ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic and in whom other antiarrhythmic therapy is not appropriate.

Dofetilide has not been shown to be effective in patients with paroxysmal atrial arrhythmias (including paroxysmal atrial fibrillation).

The marketing authorisation for Tikosyn has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide